CytRx Corp. (NASDAQ:CYTR) of Norcross, Ga. has initiated apreliminary study in humans of its dermatological agentTherMax in experimentally induced allergic skin reactions. Thestudy is designed to assess the anti-itching and anti-inflammatory properties of the drug.

(c) 1997 American Health Consultants. All rights reserved.